Is Unicycive Therapeutics Stock a Good Investment?
Unicycive Therapeutics Investment Advice | UNCY |
- Examine Unicycive Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Unicycive Therapeutics' leadership team and their track record. Good management can help Unicycive Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Unicycive Therapeutics' business and its evolving consumer preferences.
- Compare Unicycive Therapeutics' performance and market position to its competitors. Analyze how Unicycive Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Unicycive Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Unicycive Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Unicycive Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Unicycive Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Unicycive Therapeutics Stock
Researching Unicycive Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 60.0% of the company outstanding shares are owned by institutional investors. The book value of Unicycive Therapeutics was at this time reported as 0.28. The company recorded a loss per share of 0.46. Unicycive Therapeutics had not issued any dividends in recent years.
To determine if Unicycive Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Unicycive Therapeutics' research are outlined below:
| Unicycive Therapeutics generated a negative expected return over the last 90 days | |
| Unicycive Therapeutics has some characteristics of a very speculative penny stock | |
| Unicycive Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 675 K. Net Loss for the year was (30.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Unicycive Therapeutics currently holds about 10.57 M in cash with (18.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 60.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Unicycive Therapeutics, Inc. Short Interest Update |
Unicycive Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Unicycive Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Unicycive Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Unicycive Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Unicycive Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Unicycive Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-11 | 2021-09-30 | -0.1 | -0.08 | 0.02 | 20 | ||
2021-08-16 | 2021-06-30 | -0.11 | -0.13 | -0.02 | 18 | ||
2024-03-28 | 2023-12-31 | -0.17 | -0.22 | -0.05 | 29 | ||
2023-08-14 | 2023-06-30 | -0.34 | -0.29 | 0.05 | 14 | ||
2022-05-12 | 2022-03-31 | -0.16 | -0.24 | -0.08 | 50 | ||
2023-05-16 | 2023-03-31 | -0.37 | -0.28 | 0.09 | 24 | ||
2022-11-14 | 2022-09-30 | -0.28 | -0.37 | -0.09 | 32 | ||
2024-11-13 | 2024-09-30 | -0.1517 | -0.05 | 0.1017 | 67 |
Know Unicycive Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Unicycive Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Unicycive Therapeutics backward and forwards among themselves. Unicycive Therapeutics' institutional investor refers to the entity that pools money to purchase Unicycive Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 524.5 K | Xtx Topco Ltd | 2024-12-31 | 171.5 K | State Street Corp | 2024-12-31 | 125.2 K | Goldman Sachs Group Inc | 2024-12-31 | 73.6 K | Blackrock Inc | 2024-12-31 | 72.3 K | Northern Trust Corp | 2024-12-31 | 58.2 K | Creative Planning Inc | 2024-12-31 | 22.7 K | Hrt Financial Llc | 2024-12-31 | 22.1 K | Tandem Capital Management Corp | 2024-12-31 | 15.5 K | Great Point Partners Llc | 2024-12-31 | 11 M | Nantahala Capital Management, Llc | 2024-12-31 | 10.4 M |
Unicycive Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 66.75 M.Market Cap |
|
Unicycive Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.94) | (2.03) | |
| Return On Capital Employed | 5.59 | 6.42 | |
| Return On Assets | (1.94) | (2.03) | |
| Return On Equity | 7.22 | 6.75 |
Determining Unicycive Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Unicycive Therapeutics is a good buy. For example, gross profit margin measures Unicycive Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Unicycive Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Unicycive Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Unicycive Therapeutics. Check Unicycive Therapeutics' Beneish M Score to see the likelihood of Unicycive Therapeutics' management manipulating its earnings.
Evaluate Unicycive Therapeutics' management efficiency
Unicycive Therapeutics has return on total asset (ROA) of (0.6285) % which means that it has lost $0.6285 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4705) %, meaning that it created substantial loss on money invested by shareholders. Unicycive Therapeutics' management efficiency ratios could be used to measure how well Unicycive Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 6.42 in 2025, whereas Return On Tangible Assets are likely to drop (2.03) in 2025. At this time, Unicycive Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 16.2 M in 2025, whereas Non Currrent Assets Other are likely to drop (164.4 K) in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.14) | (0.13) | |
| Tangible Book Value Per Share | (0.14) | (0.13) | |
| Enterprise Value Over EBITDA | (0.37) | (0.39) | |
| Price Book Value Ratio | (5.03) | (5.28) | |
| Enterprise Value Multiple | (0.37) | (0.39) | |
| Price Fair Value | (5.03) | (5.28) | |
| Enterprise Value | 14.3 M | 12.8 M |
Unicycive Therapeutics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 2.252 |
Basic technical analysis of Unicycive Stock
As of the 26th of March, Unicycive Therapeutics has the Risk Adjusted Performance of 0.0063, coefficient of variation of (42,106), and Variance of 25.58. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Unicycive Therapeutics, as well as the relationship between them.Unicycive Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Unicycive Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Unicycive Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Unicycive Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Unicycive Therapeutics' Outstanding Corporate Bonds
Unicycive Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Unicycive Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Unicycive bonds can be classified according to their maturity, which is the date when Unicycive Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| UniCredit 7296 percent Corp BondUS904678AQ20 | View | |
| UCGIM 2569 22 SEP 26 Corp BondUS904678AU32 | View | |
| UniCredit 5459 percent Corp BondUS904678AS85 | View | |
| UNICREDIT SPA 5861 Corp BondUS904678AF64 | View | |
| UCGIM 3127 03 JUN 32 Corp BondUS904678AY53 | View | |
| UCGIM 1982 03 JUN 27 Corp BondUS904678AW97 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Unicycive Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Unicycive Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0063 | |||
| Market Risk Adjusted Performance | (0.01) | |||
| Mean Deviation | 3.93 | |||
| Coefficient Of Variation | (42,106) | |||
| Standard Deviation | 5.06 | |||
| Variance | 25.58 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | (0.03) | |||
| Total Risk Alpha | (0.04) | |||
| Treynor Ratio | (0.02) | |||
| Maximum Drawdown | 28.72 | |||
| Value At Risk | (6.56) | |||
| Potential Upside | 7.69 | |||
| Skewness | 0.6907 | |||
| Kurtosis | 1.31 |
| Risk Adjusted Performance | 0.0063 | |||
| Market Risk Adjusted Performance | (0.01) | |||
| Mean Deviation | 3.93 | |||
| Coefficient Of Variation | (42,106) | |||
| Standard Deviation | 5.06 | |||
| Variance | 25.58 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | (0.03) | |||
| Total Risk Alpha | (0.04) | |||
| Treynor Ratio | (0.02) | |||
| Maximum Drawdown | 28.72 | |||
| Value At Risk | (6.56) | |||
| Potential Upside | 7.69 | |||
| Skewness | 0.6907 | |||
| Kurtosis | 1.31 |
Consider Unicycive Therapeutics' intraday indicators
Unicycive Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Unicycive Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Unicycive Therapeutics time-series forecasting models is one of many Unicycive Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Unicycive Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Unicycive Stock media impact
Far too much social signal, news, headlines, and media speculation about Unicycive Therapeutics that are available to investors today. That information is available publicly through Unicycive media outlets and privately through word of mouth or via Unicycive internal channels. However, regardless of the origin, that massive amount of Unicycive data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Unicycive Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Unicycive Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Unicycive Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Unicycive Therapeutics alpha.
Unicycive Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Unicycive Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Unicycive Therapeutics Corporate Management
| MPA MD | Chairman, Founder | Profile | |
| Pramod Gupta | Executive Operations | Profile | |
| John CPA | Chief Officer | Profile | |
| Douglas MBA | Executive Strategy | Profile |
Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.